A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

BACKGROUND. Dysregulated hepatocyte growth factor/mesenchymal‐epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular endothelial growth factor inhibition in metastatic colorectal cancer (mCRC). We report outcomes from a double‐blind, multicenter phase II t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344636/
https://ncbi.nlm.nih.gov/pubmed/28209746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0223
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados